ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi-Aventis is buying TargeGen, a San Diego-based biotech firm developing small-molecule kinase inhibitors for the treatment of leukemia, lymphoma, and other hematological malignancies. The French company will pay $75 million upon closing the deal. Total payments to TargeGen’s owners could reach $560 million depending on the development of TG 101348, TargeGen’s lead product. TG 101348 inhibits Janus kinase 2, which is associated with blood diseases such as myelofibrosis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter